Biopeople

Pharma networker

Pharma networker

17.10.2014 - Jarrod Longcor the former Vice President of Corporate Development for Rib-X Pharmaceuticals has been appointed CBO at Avillion LLP.

Jarrod Longcor brings over 18 years of pharmaceutical and biotech experience to the London-based drug development company. In his previous role at Rib-X Pharmaceuticals, Inc (now Melinta Therapeutics), Longcor was responsible for identifying and concluding several critical collaborations for the company. Prior to Rib-X, he held key positions in several small to mid-sized biotech companies where he was responsible for business development and strategic planning. At Avillion, Longcor will be responsible for structuring, negotiating and executing strategic alliances, co-development agreements, and financial instruments, as well as providing management and strategic leadership to the organisation.

http://www.european-biotechnology-news.com/people/bio-people/2014/jarrod-longcor.html

27.05.2014 Drug giant Sanofi S.A. (Paris) has filled the newly-created position of Chief Patient Officer with Anne C. Beal, a public health specialist with a focus on providing access to high-quality health care.

Sanofi S.A.

Beal’s responsibility will be to infuse the patient perspective in Sanofi’s activities, ranging from early-stage R&D through to market availability of novel healthcare solutions. A pediatrician by profession, Beal joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI), the United States’ largest research institute focused on patient-centered outcomes research, where she was Deputy Executive Director and Chief Officer for Engagement. Prior to PCORI, Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna Inc. She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University. 

22.05.2014 F. Hoffmann-La Roche has promoted Genentech’s former VP of clinical hematology and oncology Dietmar Berger to lead the pharma giant’s clinical development for oncology and hematology.

Roche

He succeeds Sandra Homing, who was named Chief Medical Officer last January. Berger brings the company more than 20 years of experience in the field. Before joining Roche, he co-led oncology research at Bayer HealthCare AG and at Amgen Inc.

20.05.2014 Alessandra Cervino has joined Paris-based metagenomics specialist Enterome Bioscience SA as Head of Discovery.

Michael Guez

The 38-old reseacher brings the firm over 15 years of experience in the discovery and development of genetic and genomic biomarkers. Before joining Enterome, Cervino was VP R&D and Biostatistics at TCLand Expression, Head of Statistical Sciences at Scripps Florida, and group leader in statistical genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.

Glythera

Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

13.05.2014 Isarna Therapeutics GmbH (Munich) has named Elizabeth Czerepak to lead the company’s new office location in New York City as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics

Czerepak has a track record of 21 years in the biopharma industry and nine years as a venture capital investor at JP Morgan and Bear Stearns. She has served in various executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. Prior to CGI, Czerepak worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

06.05.2014 The European Food Safety Authority’s Management Board has nominated Dr. Bernhard Url as EFSA’s next Executive Director.

EFSA

Following the departure of former Director Catherine Geslain-Lanéelle, Url has been EFSA’s acting Executive Director since the autumn of 2013. A qualified veterinarian by training, he brings high-level management experience from public and private food-safety organisations to the role, most recently as Managing Director for the Austrian Agency for Health and Food Safety (AGES). Until March 2012, Url served as a member of EFSA’s Management Board.

29.04.2014 Canbex Therapeutics Ltd has hired Alberto Lledó as its new Chief Medical Officer.

Canbex SL

Lledó will lead Canbex’s preparations in proof-of-concept trials for VSN16R, a small molecule for the treatment of spasticity in multiple sclerosis. Lledó is a Senior Consultant Neurologist at the Clínica Creu Blanca (Barcelona), and spent sixteen years at Eli Lilly. He will take over as Chief Medical Officer from Dr. Miroslav Ravic, who is guiding the company through the completion of its Phase I study. 

24.04.2014 Roche’s pRED unit has a new head of oncology and translational research.

Vanderbilt University Medical Center/Susan Urmy

William Pao, currently director at the Hematology-Oncology division and Personalised Cancer Medicine unit at Vanderbilt University Medical Center, will lead Roche’s discovery, translational medicine and early development of innovative oncology medicines. Pao, who has focused on academic clinical research in the past, is one of the world’s top oncology experts.

17.04.2014 Irish antibody developer Prothena Corporation plc has named Tara Nickerson as its Chief Business Officer.

Prothena Corp.

Previously she held the position of Head of Corporate and Business Development at the company, where she was instrumental during Prothena’s demerger from Elan and Prothena’s worldwide collaboration with Roche to develop and commercialise antibodies that target alpha-synuclein. Prior to Elan, Nickerson was a senior scientist at Celera Genomics (Axys Pharmaceuticals). 

15.04.2014 Geneva-based antibody developer Novimmune SA has appointed Andrew Oakley as its new CFO.

Novimmune

The finance expert has been the CFO and Vice President of Actelion Pharmaceuticals U.S., Inc. since January of 2003. Prior to that, he held executive positions in major multinational building material companies, and spent several years as an equity analyst with banks in Australia, the UK and the US. Oakley has been a member of the Australian Institute of Chartered Accountants since 1987.

Vorherige Seite4/21Nächste Seite

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products